Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2023 | Story André Damons | Photo Supplied
Dr Michael Pienaar and Dr Edward C Netherlands
Dr Michael Pienaar, Senior Lecturer and specialist in the UFS Department of Paediatrics and Child Health, is a finalist in two categories of this year’s NSTF-South32 Awards. Dr Edward C Netherlands, Senior Lecturer in the UFS Department of Zoology and Entomology, is also in the running for his first NSTF-South32 Award.

Dr Michael Pienaar, Senior Lecturer and Specialist in the University of the Free State (UFS) Department of Paediatrics and Child Health, is a finalist in two categories of the 2023 NSTF-South32 Awards, popularly known as the ‘Science Oscars’ of South Africa.

Dr Pienaar, who has been working in paediatric critical care since 2019 and sees the care of critically ill children as his mission and calling in life, has been named a finalist in the TW Kambule-NSTF Award: Emerging Researcher and the NSTF-SAMRC Clinician-Scientist Award categories.

Another UFS staff member, Dr Edward C Netherlands, Senior Lecturer in the Department of Zoology and Entomology, is also a finalist in the TW Kambule-NSTF Award: Emerging Researcher category.

The NSTF-SAMRC Clinician-Scientist Award, sponsored by the South African Medical Research Council (SAMRC), is a new award for an outstanding contribution by a clinician-scientist, with a focus on work to enhance life and improve community health. This new category is modelled on the Emerging Researcher category.

‘Validating to have research recognised’

Dr Pienaar says it is humbling to be considered for these awards alongside formidable, accomplished, and innovative clinicians and scientists. “This is all somewhat surreal, as I was not anticipating being shortlisted as a finalist. It is validating to have had my research, which I am committed to, recognised on this platform. I am very grateful to the School of Clinical Medicine and the Faculty of Health Sciences and University of the Free State for nominating me for these awards.”

He was nominated by Dr Claire Armour Barrett, Clinical Research Director and Specialist Physician in the UFS School of Clinical Medicine.

Dr Pienaar says his current research focusses on applied machine learning in paediatric critical care. He has been working on the development of machine learning models that can be used in clinical practice to improve patient care.

“The work leading to these nominations focused on triage and identification of critically ill children in South Africa. Currently, I am working towards machine learning models implemented in point-of-care ultrasonography and mechanical ventilation.

“I am pleased just to be shortlisted for these awards. I think this provides important visibility for my work, which I feel has major long-term implications for clinical practice. I am also very happy to represent the research work being done in the Faculty of Health Sciences and the UFS on this platform.”

On what it will mean to win a ‘Science Oscar’, Dr Pienaar says, “While this would advance my career, I am very aware that all the candidates would be worthy winners. As it is, the opportunity to be a scholar is reward unto itself, and I am very privileged to be able to do the research I do. As ever, I am very grateful to the University and the Faculty of Health Sciences as well as the National Research Foundation for supporting my work.”

‘Honour and privilege’

Dr Netherlands, who was nominated by Prof Corli Witthuhn, former UFS Vice-Rector for Research and Internationalisation, says, “It is a great honour and privilege to represent the UFS.”

His work as a parasitologist and herpetologist involves specialised research in the study of blood parasites. His current research focuses on the diversity, evolution, and ecological implications of blood parasites in herpetofauna (reptiles and amphibians of a particular region).

“Being shortlisted as a finalist for this award will be a humbling achievement in my career, that may lead to new opportunities and new collaborations,” Dr Netherlands says. “Furthermore, being shortlisted provides a sense of validation and affirmation for the effort that has gone into conducting my research.”

The announcement of the winners will take place at the NSTF-South32 Awards Gala Event on 13 July 2023.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept